[
    {
        "id": 7924,
        "drug_name": "Vasopressin",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Increase blood pressure in adults",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-15",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20211215005960\/en\/",
        "note": "Approved December 15, 2021. ",
        "company_entity_id": 128,
        "company_ticker": "EGRX",
        "company_name": "Eagle Pharmaceuticals Inc.",
        "company_price": "5.7300",
        "company_change": -0.14,
        "company_percent_change": -2.39,
        "company_optionable": 1,
        "company_number_of_shares": 12986971,
        "price_change_sparkline": [
            [
                5.86,
                1706677200
            ],
            [
                6.08,
                1706763600
            ],
            [
                5.85,
                1706850000
            ],
            [
                5.6,
                1707109200
            ],
            [
                4.9,
                1707195600
            ],
            [
                5.165,
                1707282000
            ],
            [
                5.32,
                1707368400
            ],
            [
                5.32,
                1707454800
            ],
            [
                5.6,
                1707714000
            ],
            [
                5.21,
                1707800400
            ],
            [
                5.25,
                1707886800
            ],
            [
                5.85,
                1707973200
            ],
            [
                5.97,
                1708059600
            ],
            [
                5.99,
                1708405200
            ],
            [
                6.23,
                1708491600
            ],
            [
                5.87,
                1708578000
            ],
            [
                6.25,
                1708664400
            ],
            [
                6.48,
                1708923600
            ],
            [
                6.44,
                1709010000
            ],
            [
                6.27,
                1709096400
            ],
            [
                5.86,
                1709182800
            ],
            [
                6.48,
                1709269200
            ],
            [
                6.29,
                1709528400
            ],
            [
                6.51,
                1709614800
            ],
            [
                6.35,
                1709701200
            ],
            [
                6.25,
                1709787600
            ],
            [
                6.25,
                1709874000
            ],
            [
                5.87,
                1710129600
            ],
            [
                5.73,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8162,
        "drug_name": "ORENCIA (abatacept)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": " Graft Versus Host Disease (aGvHD)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-15",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20211213006061\/en\/",
        "note": "Approved December 15, 2021. ",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6702,
        "drug_name": "TARPEYO (budesonide)",
        "clinical_trial_id": "NCT03643965",
        "has_trial_insight_page": 0,
        "indication": "IgA nephropathy",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-15",
        "link": "https:\/\/www.calliditas.se\/en\/fda-grants-calliditas-therapeutics-accelerated-approval-of-tarpeyo-budesonide-to-reduce-proteinuria-in-iga-nephropathy-3927\/",
        "note": "Approved December 15, 2021. ",
        "company_entity_id": 768,
        "company_ticker": "CALT",
        "company_name": "Calliditas Therapeutics AB",
        "company_price": "22.0700",
        "company_change": -0.18000000000000005,
        "company_percent_change": -0.81,
        "company_optionable": 1,
        "company_number_of_shares": 29786294,
        "price_change_sparkline": [
            [
                22.1801,
                1706677200
            ],
            [
                21.7286,
                1706763600
            ],
            [
                20.85,
                1706850000
            ],
            [
                20.75,
                1707109200
            ],
            [
                21.5099,
                1707195600
            ],
            [
                21.57,
                1707282000
            ],
            [
                21.5,
                1707368400
            ],
            [
                21.14,
                1707454800
            ],
            [
                21.4,
                1707714000
            ],
            [
                21.05,
                1707800400
            ],
            [
                20.67,
                1707886800
            ],
            [
                20.58,
                1707973200
            ],
            [
                21.24,
                1708059600
            ],
            [
                20.92,
                1708405200
            ],
            [
                20.3,
                1708491600
            ],
            [
                20.5,
                1708578000
            ],
            [
                20.04,
                1708664400
            ],
            [
                20.715,
                1708923600
            ],
            [
                22.07,
                1709010000
            ],
            [
                21.88,
                1709096400
            ],
            [
                21.3195,
                1709182800
            ],
            [
                21.43,
                1709269200
            ],
            [
                21.1,
                1709528400
            ],
            [
                20.455,
                1709614800
            ],
            [
                22.19,
                1709701200
            ],
            [
                23.13,
                1709787600
            ],
            [
                22.1,
                1709874000
            ],
            [
                22.25,
                1710129600
            ],
            [
                22.07,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2389,
        "drug_name": "Tezspire (tezepelumab-ekko)",
        "clinical_trial_id": "NCT03347279",
        "has_trial_insight_page": 1,
        "indication": "Asthma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-17",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-approves-tezspire-tezepelumab-ekko-in-the-us-for-severe-asthma-301447689.html",
        "note": "Approved December 17, 2021. ",
        "company_entity_id": 372,
        "company_ticker": "AMGN",
        "company_name": "Amgen Inc.",
        "company_price": "276.5400",
        "company_change": 1.18,
        "company_percent_change": 0.43,
        "company_optionable": 1,
        "company_number_of_shares": 535918901,
        "price_change_sparkline": [
            [
                311.832823699025,
                1706677200
            ],
            [
                322.053272003295,
                1706763600
            ],
            [
                320.693853151174,
                1706850000
            ],
            [
                319.483275779212,
                1707109200
            ],
            [
                313.62884422628,
                1707195600
            ],
            [
                293.584858231498,
                1707282000
            ],
            [
                292.572736166415,
                1707368400
            ],
            [
                288.871544693121,
                1707454800
            ],
            [
                292.155980021969,
                1707714000
            ],
            [
                288.236487711108,
                1707800400
            ],
            [
                287.829654332006,
                1707886800
            ],
            [
                289.07,
                1707973200
            ],
            [
                283.7,
                1708059600
            ],
            [
                283.51,
                1708405200
            ],
            [
                283.46,
                1708491600
            ],
            [
                285.18,
                1708578000
            ],
            [
                289.18,
                1708664400
            ],
            [
                286.37,
                1708923600
            ],
            [
                278.49,
                1709010000
            ],
            [
                277.46,
                1709096400
            ],
            [
                273.83,
                1709182800
            ],
            [
                280.33,
                1709269200
            ],
            [
                279.39,
                1709528400
            ],
            [
                276.65,
                1709614800
            ],
            [
                276.59,
                1709701200
            ],
            [
                272.86,
                1709787600
            ],
            [
                273.75,
                1709874000
            ],
            [
                275.36,
                1710129600
            ],
            [
                276.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2389,
        "drug_name": "Tezspire (tezepelumab-ekko)",
        "clinical_trial_id": "NCT03347279",
        "has_trial_insight_page": 1,
        "indication": "Asthma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-17",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-approves-tezspire-tezepelumab-ekko-in-the-us-for-severe-asthma-301447689.html",
        "note": "Approved December 17, 2021. ",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2518,
        "drug_name": "VYVGART (efgartigimod alfa-fcab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Myasthenia gravis (MG)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-17",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20211217005641\/en\/",
        "note": "Approved December 17, 2021. ",
        "company_entity_id": 415,
        "company_ticker": "ARGX",
        "company_name": "argenx SE",
        "company_price": "387.9400",
        "company_change": 2.94,
        "company_percent_change": 0.76,
        "company_optionable": 1,
        "company_number_of_shares": 55395856,
        "price_change_sparkline": [
            [
                380.51,
                1706677200
            ],
            [
                385.58,
                1706763600
            ],
            [
                378.84,
                1706850000
            ],
            [
                403.37,
                1707109200
            ],
            [
                393.12,
                1707195600
            ],
            [
                391.95,
                1707282000
            ],
            [
                394.89,
                1707368400
            ],
            [
                401.48,
                1707454800
            ],
            [
                392.7,
                1707714000
            ],
            [
                386.83,
                1707800400
            ],
            [
                390.27,
                1707886800
            ],
            [
                393.47,
                1707973200
            ],
            [
                392.23,
                1708059600
            ],
            [
                395.4,
                1708405200
            ],
            [
                399.95,
                1708491600
            ],
            [
                406.01,
                1708578000
            ],
            [
                409.52,
                1708664400
            ],
            [
                410.35,
                1708923600
            ],
            [
                411.2,
                1709010000
            ],
            [
                397.7,
                1709096400
            ],
            [
                380.01,
                1709182800
            ],
            [
                393.49,
                1709269200
            ],
            [
                390.32,
                1709528400
            ],
            [
                388.69,
                1709614800
            ],
            [
                390.66,
                1709701200
            ],
            [
                388.68,
                1709787600
            ],
            [
                387.8,
                1709874000
            ],
            [
                385,
                1710129600
            ],
            [
                387.94,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2518,
        "drug_name": "VYVGART (efgartigimod alfa-fcab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Myasthenia gravis (MG)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-17",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20211217005641\/en\/",
        "note": "Approved December 17, 2021. ",
        "company_entity_id": 484,
        "company_ticker": "ZLAB",
        "company_name": "Zai Lab Limited",
        "company_price": "19.5400",
        "company_change": -0.47,
        "company_percent_change": -2.35,
        "company_optionable": 1,
        "company_number_of_shares": 99208743,
        "price_change_sparkline": [
            [
                21.57,
                1706677200
            ],
            [
                22.51,
                1706763600
            ],
            [
                22.5,
                1706850000
            ],
            [
                22.12,
                1707109200
            ],
            [
                21.61,
                1707195600
            ],
            [
                19.66,
                1707282000
            ],
            [
                19.605,
                1707368400
            ],
            [
                18.68,
                1707454800
            ],
            [
                18.21,
                1707714000
            ],
            [
                17.73,
                1707800400
            ],
            [
                19.39,
                1707886800
            ],
            [
                19.89,
                1707973200
            ],
            [
                20.64,
                1708059600
            ],
            [
                19.24,
                1708405200
            ],
            [
                19.91,
                1708491600
            ],
            [
                20.08,
                1708578000
            ],
            [
                19.94,
                1708664400
            ],
            [
                20.99,
                1708923600
            ],
            [
                22.49,
                1709010000
            ],
            [
                20.8,
                1709096400
            ],
            [
                20.98,
                1709182800
            ],
            [
                21.1,
                1709269200
            ],
            [
                20.42,
                1709528400
            ],
            [
                18.91,
                1709614800
            ],
            [
                19.8,
                1709701200
            ],
            [
                19.16,
                1709787600
            ],
            [
                18.91,
                1709874000
            ],
            [
                20.01,
                1710129600
            ],
            [
                19.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3546,
        "drug_name": "OXBRYTA (Voxelotor)",
        "clinical_trial_id": "NCT02850406",
        "has_trial_insight_page": 0,
        "indication": "Sickle cell disease - children age 4-11",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-17",
        "link": "https:\/\/ir.gbt.com\/news-releases\/news-release-details\/us-fda-approves-supplemental-new-drug-application-expanded",
        "note": "Approved December 17, 2021.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3601,
        "drug_name": "CAPLYTA  (Lumateperone)",
        "clinical_trial_id": "NCT02600507",
        "has_trial_insight_page": 0,
        "indication": "Bipolar depression",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-20",
        "link": "https:\/\/www.globenewswire.com\/news-release\/2021\/12\/20\/2355071\/30597\/en\/Intra-Cellular-Therapies-Announces-U-S-FDA-Approval-of-CAPLYTA-lumateperone-for-the-Treatment-of-Bipolar-Depression-in-Adults.html#:~:text=Intra%2DCellular%20Therapies%20Inc.,-New%20York%2C%20New&text=CAPLYTA%20is%20the%20only%20FDA,Intra%2DCellular%20Therapies%2C%20Inc.",
        "note": "Approved December 20, 2021. ",
        "company_entity_id": 176,
        "company_ticker": "ITCI",
        "company_name": "Intra-Cellular Therapies Inc.",
        "company_price": "64.3700",
        "company_change": -1.06,
        "company_percent_change": -1.62,
        "company_optionable": 1,
        "company_number_of_shares": 96807191,
        "price_change_sparkline": [
            [
                67.34,
                1706677200
            ],
            [
                68.19,
                1706763600
            ],
            [
                67.25,
                1706850000
            ],
            [
                69,
                1707109200
            ],
            [
                70.09,
                1707195600
            ],
            [
                68.57,
                1707282000
            ],
            [
                71.6,
                1707368400
            ],
            [
                72.77,
                1707454800
            ],
            [
                72.73,
                1707714000
            ],
            [
                70.4,
                1707800400
            ],
            [
                71.99,
                1707886800
            ],
            [
                74.89,
                1707973200
            ],
            [
                75.65,
                1708059600
            ],
            [
                73.7,
                1708405200
            ],
            [
                73.28,
                1708491600
            ],
            [
                71.93,
                1708578000
            ],
            [
                70.16,
                1708664400
            ],
            [
                71.56,
                1708923600
            ],
            [
                72.9,
                1709010000
            ],
            [
                71.13,
                1709096400
            ],
            [
                69.52,
                1709182800
            ],
            [
                71.49,
                1709269200
            ],
            [
                67.23,
                1709528400
            ],
            [
                66.62,
                1709614800
            ],
            [
                66.03,
                1709701200
            ],
            [
                66.72,
                1709787600
            ],
            [
                67.48,
                1709874000
            ],
            [
                65.43,
                1710129600
            ],
            [
                64.37,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3446,
        "drug_name": "YUSIMRY (adalimumab-aqvh)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Psoriasis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-20",
        "link": "https:\/\/investors.coherus.com\/news-releases\/news-release-details\/coherus-announces-us-fda-approval-yusimrytm-adalimumab-aqvh",
        "note": "Approved December 20, 2021. ",
        "company_entity_id": 89,
        "company_ticker": "CHRS",
        "company_name": "Coherus BioSciences Inc.",
        "company_price": "2.2400",
        "company_change": -0.030000000000000027,
        "company_percent_change": -1.3199999999999998,
        "company_optionable": 1,
        "company_number_of_shares": 111364152,
        "price_change_sparkline": [
            [
                2.15,
                1706677200
            ],
            [
                2.09,
                1706763600
            ],
            [
                2.06,
                1706850000
            ],
            [
                2.02,
                1707109200
            ],
            [
                2.32,
                1707195600
            ],
            [
                2.32,
                1707282000
            ],
            [
                2.38,
                1707368400
            ],
            [
                2.62,
                1707454800
            ],
            [
                2.82,
                1707714000
            ],
            [
                2.56,
                1707800400
            ],
            [
                2.72,
                1707886800
            ],
            [
                2.85,
                1707973200
            ],
            [
                2.76,
                1708059600
            ],
            [
                2.59,
                1708405200
            ],
            [
                2.48,
                1708491600
            ],
            [
                2.47,
                1708578000
            ],
            [
                2.58,
                1708664400
            ],
            [
                2.5,
                1708923600
            ],
            [
                2.62,
                1709010000
            ],
            [
                2.36,
                1709096400
            ],
            [
                2.28,
                1709182800
            ],
            [
                2.41,
                1709269200
            ],
            [
                2.27,
                1709528400
            ],
            [
                2.18,
                1709614800
            ],
            [
                2.21,
                1709701200
            ],
            [
                2.21,
                1709787600
            ],
            [
                2.39,
                1709874000
            ],
            [
                2.27,
                1710129600
            ],
            [
                2.24,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5455,
        "drug_name": "OTEZLA (apremilast)",
        "clinical_trial_id": "NCT03721172",
        "has_trial_insight_page": 0,
        "indication": "Plaque psoriasis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-20",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-approves-otezla-apremilast-for-the-treatment-of-adult-patients-with-plaque-psoriasis-regardless-of-severity-level-301448542.html",
        "note": "Approved December 20, 2021. ",
        "company_entity_id": 372,
        "company_ticker": "AMGN",
        "company_name": "Amgen Inc.",
        "company_price": "276.5400",
        "company_change": 1.18,
        "company_percent_change": 0.43,
        "company_optionable": 1,
        "company_number_of_shares": 535918901,
        "price_change_sparkline": [
            [
                311.832823699025,
                1706677200
            ],
            [
                322.053272003295,
                1706763600
            ],
            [
                320.693853151174,
                1706850000
            ],
            [
                319.483275779212,
                1707109200
            ],
            [
                313.62884422628,
                1707195600
            ],
            [
                293.584858231498,
                1707282000
            ],
            [
                292.572736166415,
                1707368400
            ],
            [
                288.871544693121,
                1707454800
            ],
            [
                292.155980021969,
                1707714000
            ],
            [
                288.236487711108,
                1707800400
            ],
            [
                287.829654332006,
                1707886800
            ],
            [
                289.07,
                1707973200
            ],
            [
                283.7,
                1708059600
            ],
            [
                283.51,
                1708405200
            ],
            [
                283.46,
                1708491600
            ],
            [
                285.18,
                1708578000
            ],
            [
                289.18,
                1708664400
            ],
            [
                286.37,
                1708923600
            ],
            [
                278.49,
                1709010000
            ],
            [
                277.46,
                1709096400
            ],
            [
                273.83,
                1709182800
            ],
            [
                280.33,
                1709269200
            ],
            [
                279.39,
                1709528400
            ],
            [
                276.65,
                1709614800
            ],
            [
                276.59,
                1709701200
            ],
            [
                272.86,
                1709787600
            ],
            [
                273.75,
                1709874000
            ],
            [
                275.36,
                1710129600
            ],
            [
                276.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8729,
        "drug_name": "Rifabutin Capsules",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Mycobacterium avium complex",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-21",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20211221005173\/en\/",
        "note": "Approved December 21, 2021. ",
        "company_entity_id": 792,
        "company_ticker": "ANIP",
        "company_name": "ANI Pharmaceuticals Inc.",
        "company_price": "66.5400",
        "company_change": 0.41,
        "company_percent_change": 0.62,
        "company_optionable": 1,
        "company_number_of_shares": 21078986,
        "price_change_sparkline": [
            [
                55.82,
                1706677200
            ],
            [
                56.51,
                1706763600
            ],
            [
                55.42,
                1706850000
            ],
            [
                56.04,
                1707109200
            ],
            [
                56.87,
                1707195600
            ],
            [
                56.03,
                1707282000
            ],
            [
                55.91,
                1707368400
            ],
            [
                56.51,
                1707454800
            ],
            [
                57.03,
                1707714000
            ],
            [
                55.02,
                1707800400
            ],
            [
                56.1,
                1707886800
            ],
            [
                57.55,
                1707973200
            ],
            [
                59.72,
                1708059600
            ],
            [
                58.37,
                1708405200
            ],
            [
                57.63,
                1708491600
            ],
            [
                58.15,
                1708578000
            ],
            [
                59.13,
                1708664400
            ],
            [
                60.25,
                1708923600
            ],
            [
                59.94,
                1709010000
            ],
            [
                60.28,
                1709096400
            ],
            [
                67.67,
                1709182800
            ],
            [
                67.17,
                1709269200
            ],
            [
                66.42,
                1709528400
            ],
            [
                65.34,
                1709614800
            ],
            [
                65.81,
                1709701200
            ],
            [
                66.71,
                1709787600
            ],
            [
                67.42,
                1709874000
            ],
            [
                66.13,
                1710129600
            ],
            [
                66.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 10339,
        "drug_name": "Canalevia-CA1",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Chemotherapy-induced diarrhea (CID) in dogs",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-21",
        "link": "https:\/\/jaguarhealth.gcs-web.com\/news-releases\/news-release-details\/jaguar-health-announces-fda-conditional-approval-canalevia-ca1",
        "note": "FDA conditionally approved on December 21, 2021.",
        "company_entity_id": 492,
        "company_ticker": "JAGX",
        "company_name": "Jaguar Health Inc.",
        "company_price": "0.0683",
        "company_change": 0,
        "company_percent_change": -4.34,
        "company_optionable": 0,
        "company_number_of_shares": 50755589,
        "price_change_sparkline": [
            [
                0.1035,
                1706677200
            ],
            [
                0.0997,
                1706763600
            ],
            [
                0.0968,
                1706850000
            ],
            [
                0.0891,
                1707109200
            ],
            [
                0.0929,
                1707195600
            ],
            [
                0.0897,
                1707282000
            ],
            [
                0.0887,
                1707368400
            ],
            [
                0.0837,
                1707454800
            ],
            [
                0.0894,
                1707714000
            ],
            [
                0.0819,
                1707800400
            ],
            [
                0.0811,
                1707886800
            ],
            [
                0.082,
                1707973200
            ],
            [
                0.0781,
                1708059600
            ],
            [
                0.0704,
                1708405200
            ],
            [
                0.0673,
                1708491600
            ],
            [
                0.057,
                1708578000
            ],
            [
                0.06,
                1708664400
            ],
            [
                0.06,
                1708923600
            ],
            [
                0.0579,
                1709010000
            ],
            [
                0.0577,
                1709096400
            ],
            [
                0.059,
                1709182800
            ],
            [
                0.0885,
                1709269200
            ],
            [
                0.143,
                1709528400
            ],
            [
                0.1261,
                1709614800
            ],
            [
                0.0896,
                1709701200
            ],
            [
                0.0817,
                1709787600
            ],
            [
                0.0815,
                1709874000
            ],
            [
                0.071,
                1710129600
            ],
            [
                0.0683,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8730,
        "drug_name": "Apretude",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "HIV",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-21",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20211220005863\/en\/",
        "note": "Approved December 21, 2021. ",
        "company_entity_id": 379,
        "company_ticker": "GSK",
        "company_name": "GSK plc American Depositary Shares (Each representing two)",
        "company_price": "43.2700",
        "company_change": 0.35,
        "company_percent_change": 0.82,
        "company_optionable": 1,
        "company_number_of_shares": 2058516719,
        "price_change_sparkline": [
            [
                39.0637603938206,
                1706677200
            ],
            [
                40.2424083367376,
                1706763600
            ],
            [
                40.3315497777986,
                1706850000
            ],
            [
                41.1734411655964,
                1707109200
            ],
            [
                41.3517240477183,
                1707195600
            ],
            [
                41.6191483709012,
                1707282000
            ],
            [
                41.4210562796546,
                1707368400
            ],
            [
                41.5101977207156,
                1707454800
            ],
            [
                40.67821093748,
                1707714000
            ],
            [
                40.9951582834745,
                1707800400
            ],
            [
                41.40124707053,
                1707886800
            ],
            [
                41.371533256843,
                1707973200
            ],
            [
                41.5399115344025,
                1708059600
            ],
            [
                41.6191483709012,
                1708405200
            ],
            [
                41.5399115344025,
                1708491600
            ],
            [
                42.16,
                1708578000
            ],
            [
                42.22,
                1708664400
            ],
            [
                42.34,
                1708923600
            ],
            [
                42.38,
                1709010000
            ],
            [
                42.34,
                1709096400
            ],
            [
                41.9,
                1709182800
            ],
            [
                42.03,
                1709269200
            ],
            [
                42.44,
                1709528400
            ],
            [
                42.6,
                1709614800
            ],
            [
                42.62,
                1709701200
            ],
            [
                43.58,
                1709787600
            ],
            [
                43.14,
                1709874000
            ],
            [
                42.92,
                1710129600
            ],
            [
                43.27,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8730,
        "drug_name": "Apretude",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "HIV",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-21",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20211220005863\/en\/",
        "note": "Approved December 21, 2021. ",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3172,
        "drug_name": "Leqvio (inclisiran)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Hypercholesterolemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-22",
        "link": "https:\/\/www.globenewswire.com\/news-release\/2021\/12\/22\/2357041\/0\/en\/FDA-approves-Novartis-Leqvio-inclisiran-first-in-class-siRNA-to-lower-cholesterol-and-keep-it-low-with-two-doses-a-year.html",
        "note": "Approved December 22, 2021. ",
        "company_entity_id": 32,
        "company_ticker": "ALNY",
        "company_name": "Alnylam Pharmaceuticals Inc.",
        "company_price": "146.6500",
        "company_change": -2.45,
        "company_percent_change": -1.6400000000000001,
        "company_optionable": 1,
        "company_number_of_shares": 125945793,
        "price_change_sparkline": [
            [
                172.91,
                1706677200
            ],
            [
                174.92,
                1706763600
            ],
            [
                173.06,
                1706850000
            ],
            [
                170.7,
                1707109200
            ],
            [
                172.18,
                1707195600
            ],
            [
                168.6,
                1707282000
            ],
            [
                169.5,
                1707368400
            ],
            [
                170.03,
                1707454800
            ],
            [
                169.34,
                1707714000
            ],
            [
                162,
                1707800400
            ],
            [
                164.15,
                1707886800
            ],
            [
                147.43,
                1707973200
            ],
            [
                147,
                1708059600
            ],
            [
                149.69,
                1708405200
            ],
            [
                154.74,
                1708491600
            ],
            [
                162.81,
                1708578000
            ],
            [
                157.65,
                1708664400
            ],
            [
                158.66,
                1708923600
            ],
            [
                159,
                1709010000
            ],
            [
                155.23,
                1709096400
            ],
            [
                151.09,
                1709182800
            ],
            [
                152.61,
                1709269200
            ],
            [
                150.04,
                1709528400
            ],
            [
                149.68,
                1709614800
            ],
            [
                149.66,
                1709701200
            ],
            [
                149.86,
                1709787600
            ],
            [
                149.82,
                1709874000
            ],
            [
                149.1,
                1710129600
            ],
            [
                146.65,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3172,
        "drug_name": "Leqvio (inclisiran)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Hypercholesterolemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-22",
        "link": "https:\/\/www.globenewswire.com\/news-release\/2021\/12\/22\/2357041\/0\/en\/FDA-approves-Novartis-Leqvio-inclisiran-first-in-class-siRNA-to-lower-cholesterol-and-keep-it-low-with-two-doses-a-year.html",
        "note": "Approved December 22, 2021. ",
        "company_entity_id": 386,
        "company_ticker": "NVS",
        "company_name": "Novartis AG",
        "company_price": "99.7700",
        "company_change": -1.6,
        "company_percent_change": -1.58,
        "company_optionable": 1,
        "company_number_of_shares": 2044033986,
        "price_change_sparkline": [
            [
                99.701426650332,
                1706677200
            ],
            [
                101.493681927897,
                1706763600
            ],
            [
                99.9423211768864,
                1706850000
            ],
            [
                99.701426650332,
                1707109200
            ],
            [
                99.9615927390107,
                1707195600
            ],
            [
                99.6917908692698,
                1707282000
            ],
            [
                97.6682768462129,
                1707368400
            ],
            [
                97.3502960711611,
                1707454800
            ],
            [
                96.8685070180523,
                1707714000
            ],
            [
                95.4520472019125,
                1707800400
            ],
            [
                95.4424114208503,
                1707886800
            ],
            [
                96.0012867224565,
                1707973200
            ],
            [
                96.5408904619384,
                1708059600
            ],
            [
                98.9787430706688,
                1708405200
            ],
            [
                98.824570573674,
                1708491600
            ],
            [
                99.0558293191662,
                1708578000
            ],
            [
                100.115765236006,
                1708664400
            ],
            [
                99.4894394669641,
                1708923600
            ],
            [
                99.3930816563424,
                1709010000
            ],
            [
                98.49695401756,
                1709096400
            ],
            [
                97.2924813847881,
                1709182800
            ],
            [
                98.3427815205652,
                1709269200
            ],
            [
                98.2560594910056,
                1709528400
            ],
            [
                98.3813246448139,
                1709614800
            ],
            [
                98.9016568221714,
                1709701200
            ],
            [
                99.93,
                1709787600
            ],
            [
                100.71,
                1709874000
            ],
            [
                101.37,
                1710129600
            ],
            [
                99.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3066,
        "drug_name": "RECORLEV (levoketoconazole)",
        "clinical_trial_id": "NCT01838551",
        "has_trial_insight_page": 0,
        "indication": "Endogenous Cushing\u2019s syndrome",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2021-12-30",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20211230005308\/en\/",
        "note": "Approved December 30, 2021.",
        "company_entity_id": 562,
        "company_ticker": "XERS",
        "company_name": "Xeris Biopharma Holdings Inc.",
        "company_price": "2.2100",
        "company_change": -0.040000000000000036,
        "company_percent_change": -1.78,
        "company_optionable": 1,
        "company_number_of_shares": 140453467,
        "price_change_sparkline": [
            [
                2.46,
                1706677200
            ],
            [
                2.51,
                1706763600
            ],
            [
                2.45,
                1706850000
            ],
            [
                2.47,
                1707109200
            ],
            [
                2.64,
                1707195600
            ],
            [
                2.63,
                1707282000
            ],
            [
                2.73,
                1707368400
            ],
            [
                2.87,
                1707454800
            ],
            [
                2.95,
                1707714000
            ],
            [
                2.87,
                1707800400
            ],
            [
                3.21,
                1707886800
            ],
            [
                3.21,
                1707973200
            ],
            [
                3.22,
                1708059600
            ],
            [
                3.16,
                1708405200
            ],
            [
                3,
                1708491600
            ],
            [
                3.04,
                1708578000
            ],
            [
                3.01,
                1708664400
            ],
            [
                3.11,
                1708923600
            ],
            [
                3.13,
                1709010000
            ],
            [
                3.02,
                1709096400
            ],
            [
                3.075,
                1709182800
            ],
            [
                3.18,
                1709269200
            ],
            [
                3.04,
                1709528400
            ],
            [
                3.08,
                1709614800
            ],
            [
                2.48,
                1709701200
            ],
            [
                2.44,
                1709787600
            ],
            [
                2.35,
                1709874000
            ],
            [
                2.25,
                1710129600
            ],
            [
                2.21,
                1710216000
            ]
        ],
        "statuses": [
            {
                "label": "Orphan Drug Designation (ODD)",
                "abbreviation": "ODD",
                "description": "Orphan Drug Designation (ODD)",
                "description_html": "<p>Orphan Drug Designation (ODD)<\/p>\n"
            }
        ]
    },
    {
        "id": 6399,
        "drug_name": "RINVOQ (Upadacitinib)",
        "clinical_trial_id": "NCT03569293",
        "has_trial_insight_page": 0,
        "indication": "Atopic dermatitis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-01-14",
        "link": "https:\/\/news.abbvie.com\/news\/press-releases\/us-fda-approves-rinvoq-upadacitinib-to-treat-adults-and-children-12-years-and-older-with-refractory-moderate-to-severe-atopic-dermatitis.htm",
        "note": "Approved January 14, 2022.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3030,
        "drug_name": "RINVOQ (Upadacitinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Atopic Dermatitis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-01-14",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/us-fda-approves-rinvoq-upadacitinib-to-treat-adults-and-children-12-years-and-older-with-refractory-moderate-to-severe-atopic-dermatitis-301461377.html",
        "note": "Approved January 14, 2022. ",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6096,
        "drug_name": "CIBINQO (abrocitinib)",
        "clinical_trial_id": "NCT03575871",
        "has_trial_insight_page": 0,
        "indication": "Atopic Dermatitis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-01-14",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20220114005394\/en\/",
        "note": "Approved January 14, 2022. ",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8316,
        "drug_name": "SKYRIZI (risankizumab)",
        "clinical_trial_id": "NCT03675308",
        "has_trial_insight_page": 0,
        "indication": "Psoriatic Arthritis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-01-21",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/us-fda-approves-second-indication-for-skyrizi-risankizumab-rzaa-to-treat-adults-with-active-psoriatic-arthritis-301466021.html",
        "note": "Approved January 21, 2022. ",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6561,
        "drug_name": "VEKLURY (remdesivir)",
        "clinical_trial_id": "NCT04292899",
        "has_trial_insight_page": 0,
        "indication": "COVID-19 Coronavirus",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-01-21",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20220121005359\/en\/",
        "note": "Approval extended to non-hospitalized and pediatric patients January 21, 2022. ",
        "company_entity_id": 378,
        "company_ticker": "GILD",
        "company_name": "Gilead Sciences Inc.",
        "company_price": "75.0800",
        "company_change": -0.24,
        "company_percent_change": -0.31999999999999995,
        "company_optionable": 1,
        "company_number_of_shares": 1245774616,
        "price_change_sparkline": [
            [
                78.26,
                1706677200
            ],
            [
                78.16,
                1706763600
            ],
            [
                76.96,
                1706850000
            ],
            [
                76.71,
                1707109200
            ],
            [
                77.72,
                1707195600
            ],
            [
                74.42,
                1707282000
            ],
            [
                73.8,
                1707368400
            ],
            [
                73.67,
                1707454800
            ],
            [
                74.45,
                1707714000
            ],
            [
                73.53,
                1707800400
            ],
            [
                73.04,
                1707886800
            ],
            [
                73.37,
                1707973200
            ],
            [
                71.58,
                1708059600
            ],
            [
                72.04,
                1708405200
            ],
            [
                73.2,
                1708491600
            ],
            [
                72.78,
                1708578000
            ],
            [
                73.55,
                1708664400
            ],
            [
                72.95,
                1708923600
            ],
            [
                73.02,
                1709010000
            ],
            [
                72.7,
                1709096400
            ],
            [
                72.1,
                1709182800
            ],
            [
                72.31,
                1709269200
            ],
            [
                72.25,
                1709528400
            ],
            [
                72.99,
                1709614800
            ],
            [
                72.63,
                1709701200
            ],
            [
                73.66,
                1709787600
            ],
            [
                75.12,
                1709874000
            ],
            [
                75.32,
                1710129600
            ],
            [
                75.08,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7268,
        "drug_name": "Parsaclisib",
        "clinical_trial_id": "NCT03144674",
        "has_trial_insight_page": 0,
        "indication": "Marginal Zone Lymphoma",
        "label": "NDA Filing",
        "value": "ndaFiling",
        "simplified_stage": "phase4",
        "stageid": 10,
        "stage_name": "NDA Filing",
        "date": "2022-01-25",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20220125006021\/en\/",
        "note": "NDA voluntarily withdrawn, noted January 25, 2022",
        "company_entity_id": 167,
        "company_ticker": "INCY",
        "company_name": "Incyte Corporation",
        "company_price": "59.3300",
        "company_change": -1.46,
        "company_percent_change": -2.4,
        "company_optionable": 1,
        "company_number_of_shares": 224526128,
        "price_change_sparkline": [
            [
                58.77,
                1706677200
            ],
            [
                59.16,
                1706763600
            ],
            [
                58.35,
                1706850000
            ],
            [
                58.06,
                1707109200
            ],
            [
                59.63,
                1707195600
            ],
            [
                57.34,
                1707282000
            ],
            [
                57.36,
                1707368400
            ],
            [
                57.66,
                1707454800
            ],
            [
                57.84,
                1707714000
            ],
            [
                59.34,
                1707800400
            ],
            [
                57.89,
                1707886800
            ],
            [
                58.97,
                1707973200
            ],
            [
                57.96,
                1708059600
            ],
            [
                58.82,
                1708405200
            ],
            [
                60.33,
                1708491600
            ],
            [
                60.91,
                1708578000
            ],
            [
                60.59,
                1708664400
            ],
            [
                60.53,
                1708923600
            ],
            [
                61,
                1709010000
            ],
            [
                59.98,
                1709096400
            ],
            [
                58.36,
                1709182800
            ],
            [
                59.05,
                1709269200
            ],
            [
                59.72,
                1709528400
            ],
            [
                58.9,
                1709614800
            ],
            [
                59.26,
                1709701200
            ],
            [
                59.03,
                1709787600
            ],
            [
                60.02,
                1709874000
            ],
            [
                60.79,
                1710129600
            ],
            [
                59.33,
                1710216000
            ]
        ],
        "statuses": []
    }
]